Prediction of EGFR mutations in non-small cell lung cancer: a nomogram based on 18F-FDG PET and thin-section CT radiomics with machine learning

被引:0
|
作者
Li, Jianbo [1 ]
Shi, Qin [2 ]
Yang, Yi [2 ]
Xie, Jikui [2 ]
Xie, Qiang [2 ]
Ni, Ming [2 ]
Wang, Xuemei [1 ,2 ]
机构
[1] Inner Mongolia Med Univ, Affiliated Hosp, Dept Nucl Med, Hohhot, Peoples R China
[2] Univ Sci & Technol China, Affiliated Hosp USTC 1, Dept Nucl Med, Div Life Sci & Med, Hefei, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2025年 / 15卷
关键词
nomogram; non-small cell lung cancer; PET/CT; machine learning; epidermal growth factor receptor; FACTOR RECEPTOR MUTATION; COMPUTED-TOMOGRAPHY CHARACTERISTICS; ADENOCARCINOMA;
D O I
10.3389/fonc.2025.1510386
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background This study aimed to develop and validate radiomics-based nomograms for the identification of EGFR mutations in non-small cell lung cancer (NSCLC).Methods A retrospective analysis was performed on 313 NSCLC patients, who were randomly divided into training (n = 250) and validation (n = 63) groups. Radiomic features were extracted from 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) and thin-section computed tomography (CT) scans. After selecting optimal radiomic features, four machine learning algorithms, including logistic regression (LR), random forest (RF), support vector machine (SVM), and extreme gradient boosting (XGBoost), were used to develop and validate radiomics models. A combined model, incorporating the Rad score from the best performing radiomics model with clinical and radiological features, was then formulated. Finally, the integrated nomogram was generated. Its predictive performance and clinical utility were evaluated using receiver operating characteristic curves, calibration curves, and decision curve analysis.Results Among the radiomics models, the RF model showed the best performance with AUCs of 0.785 (95% CI, 0.726-0.844) and 0.776 (95% CI, 0.662-0.889) in the training and validation groups, respectively. The AUCs of the clinical and radiological models in both groups were 0.711 (95% CI, 0.645-0.776) and 0.758 (95% CI, 0.627-0.890), and 0.632 (95% CI, 0.564-0.699) and 0.677 (95% CI, 0.531-0.822), respectively. The combined model achieved the highest AUCs of 0.872 (95% CI, 0.829-0.915) and 0.831 (95% CI, 0.723-0.940) in the training and validation groups, respectively. The DeLong test confirmed the superiority of the combined model over the other three models. Both the calibration curve and the DCA indicated that the radiomics nomogram was consistent and clinically useful.Conclusions Radiomics combined with machine learning and based on 18F-FDG PET/CT images can effectively determine EGFR mutation status in NSCLC patients. Radiomics-based nomograms provide a non-invasive and visually intuitive prediction tool for screening NSCLC patients with EGFR mutations in a clinical setting.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Thoracic staging with 18F-FDG PET/MR in non-small cell lung cancer – does it change therapeutic decisions in comparison to 18F-FDG PET/CT?
    Benedikt M. Schaarschmidt
    Johannes Grueneisen
    Martin Metzenmacher
    Benedikt Gomez
    Thomas Gauler
    Christian Roesel
    Philipp Heusch
    Verena Ruhlmann
    Lale Umutlu
    Gerald Antoch
    Christian Buchbender
    European Radiology, 2017, 27 : 681 - 688
  • [32] Machine learning-based diagnostic method of pre-therapeutic 18F-FDG PET/CT for evaluating mediastinal lymph nodes in non-small cell lung cancer
    Jang Yoo
    Miju Cheon
    Yong Jin Park
    Seung Hyup Hyun
    Jae Ill Zo
    Sang-Won Um
    Hong-Hee Won
    Kyung-Han Lee
    Byung-Tae Kim
    Joon Young Choi
    European Radiology, 2021, 31 : 4184 - 4194
  • [33] Value of 18F-FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients
    Lv, Zhilei
    Fan, Jinshuo
    Xu, Juanjuan
    Wu, Feng
    Huang, Qi
    Guo, Mengfei
    Liao, Tingting
    Liu, Shuqing
    Lan, Xiaoli
    Liao, Shanshan
    Geng, Wei
    Jin, Yang
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (05) : 735 - 750
  • [34] Machine learning-based diagnostic method of pre-therapeutic 18F-FDG PET/CT for evaluating mediastinal lymph nodes in non-small cell lung cancer
    Yoo, Jang
    Cheon, Miju
    Park, Yong Jin
    Hyun, Seung Hyup
    Zo, Jae Ill
    Um, Sang-Won
    Won, Hong-Hee
    Lee, Kyung-Han
    Kim, Byung-Tae
    Choi, Joon Young
    EUROPEAN RADIOLOGY, 2021, 31 (06) : 4184 - 4194
  • [35] Role of 18F-FDG PET in Assessment of Response in Non-Small Cell Lung Cancer
    Hicks, Rodney J.
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50 : 31S - 42S
  • [36] Prediction for Mitosis-Karyorrhexis Index Status of Pediatric Neuroblastoma via Machine Learning Based 18F-FDG PET/CT Radiomics
    Feng, Lijuan
    Qian, Luodan
    Yang, Shen
    Ren, Qinghua
    Zhang, Shuxin
    Qin, Hong
    Wang, Wei
    Wang, Chao
    Zhang, Hui
    Yang, Jigang
    DIAGNOSTICS, 2022, 12 (02)
  • [37] Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer
    Pellegrino, Sara
    Fonti, Rosa
    Mazziotti, Emanuela
    Piccin, Luisa
    Mozzillo, Eleonora
    Iano, Vincenzo Dam
    Matano, Elide
    De Placido, Sabino
    Del Vecchi, Silvana
    ANNALS OF NUCLEAR MEDICINE, 2019, 33 (12) : 937 - 944
  • [38] Predictive Value of Initial 18F-FDG PET/CT for Identifying EGFR and KRAS Mutations in Patients with Non-small-cell Lung Cancer
    Topuz, Ozge Vural
    Buyukpinarbasili, Nur
    HASEKI TIP BULTENI-MEDICAL BULLETIN OF HASEKI, 2024, 62 (05): : 255 - 264
  • [39] 18F-FDG PET/CT Evaluation of Non-Small Cell Lung Cancer Initial Experience from Johannesburg
    Evbuomwan, Osayande
    Ayeni, Olusegun A.
    Purbhoo, Khushica
    Vangu, Mboyo D. T.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S495 - S495
  • [40] Integrated 18F-FDG PET/CT parameter defines metabolic oligometastatic non-small cell lung cancer
    Ma, Rong
    Zhao, Qian
    Zhao, Ren
    Li, Juan
    Wang, Yan-Yang
    NUCLEAR MEDICINE COMMUNICATIONS, 2022, 43 (09) : 1026 - 1033